Dofetilide
NDC Package 72664-231-60

11-digit billing NDC: 72664023160

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Dofetilide is maintenance of Normal Sinus Rhythm (Delay in AF/AFl Recurrence)Dofetilide Capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Marketed by Vgyaan Pharmaceuticals Llc, this product is identified by NDC 72664-231 and is authorized under FDA application ANDA215323.

Identification & Billing

NDC Package Code
72664-231-60
Package Description
60 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
72664023160
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Dofetilide
Dosage Form
-
Usage Information
Maintenance of Normal Sinus Rhythm (Delay in AF/AFl Recurrence)Dofetilide Capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because Dofetilide Capsules can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic.In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients (see CLINICAL STUDIES). Conversion of Atrial Fibrillation/FlutterDofetilide Capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.Dofetilide Capsules have not been shown to be effective in patients with paroxysmal atrial fibrillation.

Regulatory & Marketing

Labeler Name
Vgyaan Pharmaceuticals Llc
FDA Application #
ANDA215323
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-31-2021
Listing Expiration
12-31-2025
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72664-231-60 identifies a specific commercial package of 60 capsule in 1 bottle of Dofetilide, labeled by Vgyaan Pharmaceuticals Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Vgyaan Pharmaceuticals Llc on July 31, 2021. The current certification is valid through December 31, 2025.

How is this Vgyaan Pharmaceuticals Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72664023160. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72664-231-60
11-Digit CMS (5-4-2)
72664-0231-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.